Engineered and armored for an exquisitely specific target
NKILT Therapeutics is a new cell therapy biotech in seed stage. Our innovative team —led by experts in immunology, oncology, and cell therapy—is developing a novel approach to engineering natural killer (NK) cells to directly target leukemias and solid tumors.
Our initial platform is a novel Chimeric ILT-Receptor (CIR) that features a unique proprietary binding technology targeting the inducible immune checkpoint HLA-G. HLA-G is expressed in more than 50% of human cancers.
Our armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells while also activating innate immunity to target the tumor’s defense mechanisms.
The first indication will be acute myeloid leukemia (AML), followed by expansion to solid tumors such as renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and others that express HLA-G.
Join us in building the future of cell therapy
To get in touch and receive our investor deck to learn more about our program, complete this form.